Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Non-Hodgkin 13Lymphoma, Mantle-Cell 13Lymphoma, B-Cell 11Lymphoma, B-Cell, Marginal Zone 7Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma 4Leukemia, B-Cell 4Lymphoma, Follicular 3Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphoid 2Dendritic Cell Sarcoma, Interdigitating 2Multiple Myeloma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lymphoma × pirtobrutinib × Clear all
NCT04662255 2026-05-15

BRUIN-MCL-321

Eli Lilly and Company

Phase 3 Active not recruiting
500 enrolled
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07285590 2025-12-16

IMCL-2023

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Recruiting
50 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡